499.99
전일 마감가:
$483.76
열려 있는:
$487.53
하루 거래량:
1.75M
Relative Volume:
0.67
시가총액:
$188.80B
수익:
$43.21B
순이익/손실:
$6.58B
주가수익비율:
28.92
EPS:
17.29
순현금흐름:
$6.17B
1주 성능:
+2.25%
1개월 성능:
+16.92%
6개월 성능:
-6.11%
1년 성능:
-17.20%
써모 피셔 사이언티픽 Stock (TMO) Company Profile
명칭
Thermo Fisher Scientific Inc
전화
(781) 622-1000
주소
168 THIRD AVENUE, WALTHAM, MA
TMO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
![]()
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
![]()
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
![]()
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
써모 피셔 사이언티픽 Stock (TMO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-24 | 다운그레이드 | HSBC Securities | Buy → Hold |
2025-07-11 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
2025-07-09 | 다운그레이드 | UBS | Buy → Neutral |
2025-01-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
2024-12-23 | 개시 | Scotiabank | Sector Perform |
2024-10-14 | 개시 | Redburn Atlantic | Buy |
2024-10-01 | 개시 | Stephens | Overweight |
2024-08-28 | 개시 | Wells Fargo | Overweight |
2024-06-03 | 재개 | Jefferies | Buy |
2024-03-18 | 재개 | Citigroup | Neutral |
2024-01-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2024-01-08 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
2023-12-18 | 개시 | HSBC Securities | Buy |
2023-12-13 | 개시 | Wolfe Research | Outperform |
2023-10-26 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
2023-10-25 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
2023-09-28 | 개시 | Bernstein | Outperform |
2023-09-06 | 재개 | Citigroup | Buy |
2023-07-19 | 개시 | Raymond James | Outperform |
2023-07-19 | 재확인 | Robert W. Baird | Outperform |
2023-07-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2023-04-04 | 재확인 | Barclays | Overweight |
2022-12-14 | 개시 | Deutsche Bank | Buy |
2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
2022-10-27 | 다운그레이드 | The Benchmark Company | Buy → Hold |
2022-08-25 | 개시 | Credit Suisse | Neutral |
2022-04-25 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
2022-01-26 | 재개 | Barclays | Overweight |
2021-10-20 | 업그레이드 | Citigroup | Neutral → Buy |
2021-10-15 | 재개 | Cowen | Outperform |
2021-08-05 | 재개 | Credit Suisse | Outperform |
2021-07-16 | 개시 | The Benchmark Company | Buy |
2021-03-18 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-03-03 | 개시 | Barclays | Overweight |
2021-01-08 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-12-02 | 개시 | Goldman | Buy |
2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
2020-09-30 | 개시 | Atlantic Equities | Overweight |
2020-09-14 | 개시 | Morgan Stanley | Overweight |
2020-08-20 | 재개 | JP Morgan | Overweight |
2020-07-15 | 업그레이드 | Cleveland Research | Neutral → Buy |
2020-07-07 | 재확인 | Needham | Buy |
2020-04-23 | 재확인 | Needham | Buy |
2020-01-31 | 재확인 | Needham | Buy |
2020-01-22 | 개시 | Credit Suisse | Neutral |
2020-01-08 | 개시 | Wells Fargo | Equal Weight |
2020-01-07 | 개시 | Citigroup | Buy |
2019-11-15 | 개시 | Stifel | Buy |
2019-07-25 | 재확인 | Needham | Buy |
2019-07-16 | 다운그레이드 | Needham | Strong Buy → Buy |
2019-05-30 | 개시 | Wolfe Research | Outperform |
2019-05-23 | 재확인 | Needham | Strong Buy |
2019-04-22 | 재확인 | Needham | Strong Buy |
2019-04-16 | 재확인 | BofA/Merrill | Buy |
모두보기
써모 피셔 사이언티픽 주식(TMO)의 최신 뉴스
Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034 - GlobeNewswire Inc.
Advancing Process Development With The 5L DynaDrive Single-Use Bioreactor A Paradigm Shift From Glass Benchtop Bioreactors - Bioprocess Online
Lab Equipment Market and Supply Chain Forecasts 2025-2030 - GlobeNewswire
Lab Equipment Market and Supply Chain Forecasts 2025-2030 Featuring Eppendorf, Beckman Coulter, Agilent Technologies, Thermo Fisher Scientific, Waters Corp. & More - Yahoo Finance
Why Thermo Fisher Scientific Stock Was Topping the Market Today - MSN
Thermo Fisher Positioned As Biopharma's Partner Of Choice - Benzinga
The Zacks Analyst Blog Highlights IBM, Goldman Sachs Group And Thermo Fisher Scientific - Barchart.com
Biodesix Designated Thermo Fisher Center of Excellence for NGS-Based Diagnostics. - AInvest
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics - GlobeNewswire
Major Diagnostic Partnership: Biodesix Joins Elite Group as Thermo Fisher Center of Excellence for Cancer Testing - Stock Titan
This Thermo Fisher Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
The Zacks Analyst Blog Highlights IBM, Goldman Sachs Group and Thermo Fisher Scientific - Yahoo Finance
William Blair Initiates Thermo Fisher Scientific at Outperform - MarketScreener
Pharmaceutical Inspection Machines Market to Reach $1.66 Billion by 2030, Led by Key Players Mettler-Toledo, Thermo Fisher Scientific, Sartorius, Syntegon Technology, and Krones - AInvest
Stifel Reaffirms Buy on Thermo Fisher (TMO) Despite Price Target Cut - MSN
Wells Fargo Reaffirms ‘Buy’ Rating on Thermo Fisher Scientific Inc. (TMO) - MSN
Top Stock Reports for IBM, Goldman Sachs & Thermo Fisher - The Globe and Mail
Automated Biological Microscope Market Exclusive Report with - openPR.com
Is Wall Street Bullish Or Bearish On Thermo Fisher Scientific Stock? - Barchart.com
Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2025 Earnings Call Transcript - MSN
Saliva-based Screening Market CAGR 7.70% Trends with Thermo - openPR.com
Thermo Fisher Scientific's Strategic Momentum and Institutional Confidence: A Top Buy in the Evolving Biotech Landscape - AInvest
Thermo Fisher Scientific (TMO): A Buy Rating Reinforced by Strategic M&A Adjustments and Strong Earnings Momentum - AInvest
Day 7 of Gains Streak for Thermo Fisher Scientific Stock with 8.9% Return (vs. -5.8% YTD) [8/15/2025] - Trefis
Thermo Fisher's 0.82% Gain on 66th-Ranked $1.2B Volume Driven by FDA-Approved Cancer Diagnostic Expansion - AInvest
Is Thermo Fisher Scientific Inc.’s growth already priced inPortfolio Risk Summary & Expert Curated Trade Ideas - thegnnews.com
Is Now a Good Time to Reenter Thermo Fisher Scientific Inc.2025 Winners & Losers & Reliable Price Action Trade Plans - beatles.ru
Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR | MarketsandMarkets™ - PR Newswire UK
Digital health companies list reveals industry leaders and newcomers in Silicon Valley - The Business Journals
Thermo Fisher Navigates 92nd in $940M Volume Amid FDA Approval and Sanofi Strategic Expansion - AInvest
Syncell and Thermo Fisher Collaborate on High-Resolution Spatial Proteomics Workflow - AInvest
Taiwan's Syncell partners with Thermo Fisher to advance high-resolution spatial proteomics - BioSpectrum Asia
Thermo Fisher teams up with Syncell for spatial proteomics integration - Yahoo Finance
HIV Diagnostics Company Evaluation Report 2025 | Abbott, Siemens Healthineers, and Thermo Fisher Scientific Lead the Market with Innovative Portfolios and Strategic Expansion - Yahoo Finance
Recombinant DNA Technology Market Trends, Dynamic Innovation, - openPR.com
Here's How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Toast, Amazon, Thermo Fisher Scientific And An Industrial Stock On CNBC's 'Final Trades' - Benzinga
Syncell Announces Strategic Co-Marketing Agreement to Advance High-Resolution Spatial Proteomics - Business Wire
Major biopharma firm sells Sunnyvale building in real estate consolidation - The Business Journals
Saudi Arabia Clinical Chemistry Analyzer Market Forecast and Company Analysis Report 2025-2033 Featuring Thermo Fisher Scientific, Abbott, Siemens, Danaher, J&J, Sysmex ADR, HORIBA, Hitachi - GlobeNewswire
Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge - Yahoo Finance
Apoptosis Market Future Business Opportunities 2025-2032 | - openPR.com
Heron Therapeutics enters supply agreement with Patheon and Thermo Fisher - Investing.com Nigeria
Thermo Fisher Scientific (TMO) Oncomine Dx Test Gains FDA Approval for NSCLC Treatment - simplywall.st
FDA approves Thermo Fisher’s diagnostic test for new NSCLC treatment - Medical Device Network
US Durable Medical Equipment Market Forecast and Competitive Landscape Report 2025-2033 | Invacare, NOVA, Inogen, Thermo Fisher Scientific, Abbott, Medtronic, Baxter, B. Braun, Boston Scientific, BD - Yahoo Finance
Becton, Dickinson shares rise 1.26% premarket after Thermo Fisher Scientific gets US FDA approval for lung cancer test. - AInvest
Thermo Fisher Scientific: A Premium Growth Story at a Discount Valuation - AInvest
Thermo Fisher: Growth Acceleration And Margin Expansion Should Drive The Upside - Seeking Alpha
Thermo Fisher's Stock Climbs 0.36% on FDA Diagnostic Approval Surges to 119th in Activity with $790M Volume - AInvest
Thermo Fisher Receives FDA Approval for NGS-Based Companion Diagnostic for New Non-Small Cell Lung Cancer Treatment - Business Wire
써모 피셔 사이언티픽 (TMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):